Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 61

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 61
---
 effective July 1, 2024, but received COBRA premiums of $15,015 and a legal expense reimbursement of $25,000 under the terms of the Mills Consulting and Employment Separation Agreement. Mr. Vasista resigned as EVP and Chief Financial Officer, based on mutual agreement, effective September 16, 2024. Pursuant to the terms of the Vasista Separation Agreement, Mr. Vasista received severance equal to 12 months of base pay, or $500,018, which was generally consistent with the terms of his employment agreement in the event of a termination without cause, as well as COBRA premiums for up to 12 months, with a maximum benefit of $28,070, and a legal expense reimbursement of $5,000. Under the terms of Mr. Vasista’s employment agreement, in the event of a termination without cause Mr. Vasista would receive severance in the form of up to nine months of base pay and COBRA premiums. Mr. Vasista received 12 months of base pay and up to 12 months of COBRA premiums in recognition of his continuing services to the Company pursuant to the Vasista Consulting Agreement. Under the terms of the Vasista Consulting Agreement, Mr. Vasista’s outstanding equity awards continued to vest during his service as a consultant. Furthermore, in connection, as applicable, with their employment, each of our NEOs entered into our standard form of proprietary information and inventions agreement with us. This agreement provides that the respective NEO is generally prohibited for one year after termination of employment from, directly or indirectly, soliciting our employees or customers, or competing against us.

<div align='center'>43</div>

Securities Authorized for Issuance under Equity Incentive Plans The following table provides information as of December 31, 2024 with respect to the shares of our common stock that may be issued under our existing equity compensation plans. We do not have any equity compensation plans that have not been approved by stockholders.

| Plan Category                          |     |      Number of 
  Securities to 
 Be Issued upon 
    Exercise of 
    Outstanding 
       Options, 
       Warrants 
      and Other 
         Rights |    |    |         Weighted- 
           Average 
 Exercise Price of 
       Outstanding 
          Options, 
      Warrants and 
            Rights |    |        Number of 
       Securities 
        Remaining 
        Available 
       for Future 
         Issuance 
     under Equity